Cargando…
Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
INTRODUCTION: To investigate treatment outcomes after switching from ranibizumab to aflibercept intravitreal injections in patients with macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). METHODS: Eligible patients with refractory MO secondary to BRVO, post treatment with a minim...
Autores principales: | Konidaris, Vasileios E., Tsaousis, Konstantinos T., Anzidei, Rossella, de la Mata, Guillermo, Brent, Alexander J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258582/ https://www.ncbi.nlm.nih.gov/pubmed/30288685 http://dx.doi.org/10.1007/s40123-018-0149-3 |
Ejemplares similares
-
Comment on: Ranibizumab and aflibercept intravitreal injection for treatment
naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020) -
Branch Retinal Vein Occlusion as a Rare Presentation of Antisynthetase Syndrome
por: Parida, Swati, et al.
Publicado: (2021) -
Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015) -
12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021) -
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)